The U.S. IPO market has maintained strong momentum into October 2026, with year-to-date issuance exceeding 100 deals and roughly $146 billion raised amid robust AI-related demand and equity valuations. Recent pricings of biotech and infrastructure offerings, alongside a deep pipeline of S-1 filings, reflect sustained primary-market access despite 19-year highs in Treasury yields and selective investor caution following SpaceX’s record debut. Anthropic’s targeted November listing stands as the key near-term catalyst, with performance likely influencing the pace of additional Q4 activity; OpenAI has shifted focus toward 2027. Trader sentiment on high-profile names before year-end incorporates these macro and deal-specific dynamics.